Chinese vaccine proves 79.34 pct effective against COVID-19 in phase-3 study
BEIJING, Dec. 30 (Xinhua) -- A Chinese inactivated vaccine shows 79.34 percent efficacy against COVID-19, according to the interim results of the phase-3 clinical trials unveiled by the China National Biotec Group (CNBG) on Wednesday.
All materials posted on this website marked with “Source: Xinhua Finance Agency” are subject to copyrights owned by the Xinhua Finance Agency (XFA). Any reproduction, retransmissions, or republication of all or part of any document found on this website is expressly prohibited, unless XFA has explicitly granted its prior written consent. All other rights reserved.Although XFA website includes "links" providing convenient direct access to other Internet sites, XFA does not endorse, approve, certify or make warranties or representations as to the accuracy of the information on these sites.
All financial data and news content of this website is of a general nature, is intended as a source of general information only and is not intended to constitute a recommendation or opinion in relation to any investment decision. Opinions contained in this website represent those of XFA at the time of publication and are subject to changes.XFA will make reasonable efforts to include accurate and up to date information on XFA website, but XFA makes no warranties or representations as to its accuracy, adequacy or completeness, and shall not be liable for any direct, incidental, consequential, indirect or punitive damages arising out of access to, use of or inability to use XFA website, or any errors or omissions in the content thereof.